



## Teleflex to focus on Arrow® advanced interventional access solutions at International Congress on Vascular Access

April 22, 2013

LIMERICK, Pa.--(BUSINESS WIRE)--Apr. 22, 2013-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, will showcase its interventional access portfolio at the 8th International Congress on Vascular Access ("VAS") to be held in Prague, Czech Republic on April 25-27, 2013.

During the event, the Company will highlight its Arrow chronic hemodialysis catheter portfolio, which offers both split-tip and step-tip catheters for both retrograde and antegrade insertion techniques.

The latest member, the Arrow NextStep® Retrograde or Antegrade product family, consists of step-tip catheters that can easily be inserted and tunneled using retrograde or antegrade technique respectively, combined with the advantage of split-tip high flow characteristics. The unique tip is designed for smooth, over-the-wire transitions during catheter insertions and exchanges.

The Arrow Cannon® II Plus and the Arrow Edge® products are split-tip catheters that can be tunneled retrograde or antegrade, respectively.

The Company will also give special attention to the role of chlorhexidine in Teleflex vascular access products and the Arrow+gard® antimicrobial technology's ability to reduce catheter related blood infections.<sup>1</sup>

### About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,600 people worldwide and serves healthcare providers in more than 140 countries. Additional information about Teleflex can be obtained from the company's website at [teleflex.com](http://teleflex.com).

### Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, Arrow, Arrow+gard, NextStep, Cannon and Arrow Edge are trade marks or registered trademarks of Teleflex Incorporated or its affiliates. ©2013 Teleflex Incorporated. All rights reserved.

### References:

<sup>1</sup> Veenstra, D.L., Saint, S., Saha, S., Lumley, T., Sullivan, S.D. "Cost-Effectiveness of Antiseptic-Impregnated Central Venous Catheters for the Prevention of Catheter-Related Bloodstream Infection." *Journal of the American Medical Association*, January 20, 1999, Vol. 281, Issue 3, pp. 261-267.

Source: Teleflex Incorporated

Teleflex Incorporated  
Jake Elguicze  
Treasurer and Vice President, Investor Relations  
610-948-2836  
or  
Martina Teichmann-Zindler  
Director Marketing Communications International  
+49 (0)7151-406-538  
[martina.teichmann@teleflex.com](mailto:martina.teichmann@teleflex.com)